Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc. on December 31, 2024. The report covers a specific event occurring on the same date regarding the Company's clinical development activities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a regulatory disclosure event rather than financial performance data.
Material Changes
On December 31, 2024, the Company announced plans to extend enrollment in its Phase 2a human challenge study for CDI-42344, an investigational, broad-spectrum, oral influenza PB2 inhibitor. This update was disclosed pursuant to Regulation FD.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical trial enrollment extension. The filing does not contain updated financial guidance, specific risk factors, or details on contingencies beyond the referenced press release.
Investor Verification Checklist
- Verify the details of the Phase 2a human challenge study enrollment extension in the press release furnished as Exhibit 99.1.
- Confirm the current status and timeline of the CDI-42344 clinical program.
- Review the Company's most recent 10-K or 10-Q for up-to-date financial position and liquidity metrics, as this 8-K does not contain them.